|COVID–19 NEWS||Lorong TAR Aidilfitri bazaar traders want better access for visitors to boost sales | COVID-19: Another new variant detected in Indonesia | COVID: Sarawak to vaccinate 929,435 individuals under phase two | EMCO in several areas in Sarawak, Kelantan, Sabah from Sunday | EMCO in several areas in Sarawak, Kelantan, Sabah from Sunday ||
By Mohd Shukri Ishak
JAKARTA, April 8 -- Indonesia has started practising COVID-19 screening through the GeNose C19 method, as a prerequisite for those who use public transport to cross provinces or regions.
GeNoSe C19 is a device made by Indonesia's Gadjah Mada University (UGM) to detect the COVID virus through inhalation and has been approved by the republic's Ministry of Health.
The COVID-19 breath detector or also called the COVID virus breathlyser has been studied and developed in various countries such as Indonesia, the United States, the Netherlands, Finland, Germany, Britain, Australia, and Canada.
Starting April 5, COVID screening services through GeNose C19 (apart from swab testing, antigen testing and rapid test (blood test)), began to be implemented at train stations in Indonesia.
Vice President of Public Relations of Indonesian railway operator PT Keretapi Indonesia, Joni Martinus in a statement said the GeNose C19 service at its 44 train stations charged Rp30,000 (RM9).
The results of GeNose C19 screening can be obtained in less than 24 hours.
Starting today, the Ngurah Rai International Airport on the island of Bali, is also providing the service as an option for aircraft passengers in addition to smear testing, antigen or rapid test.
PT Angkasa Pura Ngurah Rai public relations officer, Taufan Yudistira in a statement said the implementation was in line with the permission of the Ministry of Transportation regarding domestic travel requirements.
"We require those who will travel to or from Bali Island to show a negative result on examination through swab test, PCR, Rapid Antigen Test or negative result of GeNose C-19 before travelling," he said.